drugset / Trial / NCT02442531
A Study of CriPec® Docetaxel Given to Patients With Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
The goal of this Phase1 clinical research study is to find the highest safe dose of CriPec® docetaxel that can be given in the treatment of patients with solid tumours.
Timeline
- Start
- 2015-08
- Primary completion
- 2018-07
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 15 mg/m2 | Intravenous |